Abstract
To discuss the outcomes of primary squamous cell carcinoma (SCC) of the major salivary glands treated by surgery with or without postoperative adjuvant radiotherapy. We performed a retrospective analysis of 579 cases with malignancy originating in the major salivary glands. A total of 34 cases were eligible for the present study. The outcomes were analyzed in terms of disease failure patterns and survival rates between the 2 treatment groups. The treatment was surgery alone in 16 patients and a combination of surgery and postoperative adjuvant radiotherapy in 18. The locoregional recurrence rate was 43.8% in the surgery group and 22.2% in the surgery plus radiotherapy group. The distant metastasis rate was 6.3% in the surgery group and 44.4% in the surgery plus radiotherapy group. The 5-year disease-specific survival and disease-free survival (DFS) rate for all patients was 50.3% and 35.3%, respectively. The 5-year disease-specific survival rate was 48.9% in the surgery group and 48.2% in the surgery plus radiotherapy group. The 5-year DFS rate was 25.0% in the surgery group and 31.2% in the surgery plus radiotherapy group. The log-rank test showed no significant differences in the disease-specific survival or DFS rates between the 2 groups (P= .724 for disease-specific survival and P= .269 for DFS). Planned postoperative adjuvant radiotherapy is anticipated to be able to improve locoregional control rates and DFS for patients with primary SCC of the major salivary glands.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.